COVID-19 Emergency Response, Centers for Disease Control and Prevention, Atlanta, GA, USA.
Vanderbilt University, Nashville, TN, USA.
Nat Commun. 2022 Jul 27;13(1):4350. doi: 10.1038/s41467-022-31929-6.
The evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has resulted in the emergence of new variant lineages that have exacerbated the COVID-19 pandemic. Some of those variants were designated as variants of concern/interest (VOC/VOI) by national or international authorities based on many factors including their potential impact on vaccine-mediated protection from disease. To ascertain and rank the risk of VOCs and VOIs, we analyze the ability of 14 variants (614G, Alpha, Beta, Gamma, Delta, Epsilon, Zeta, Eta, Theta, Iota, Kappa, Lambda, Mu, and Omicron) to escape from mRNA vaccine-induced antibodies. The variants show differential reductions in neutralization and replication by post-vaccination sera. Although the Omicron variant (BA.1, BA.1.1, and BA.2) shows the most escape from neutralization, sera collected after a third dose of vaccine (booster sera) retain moderate neutralizing activity against that variant. Therefore, vaccination remains an effective strategy during the COVID-19 pandemic.
严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）的进化导致了新的变异株系的出现，这些变异株系加剧了 COVID-19 大流行。其中一些变体被国家或国际当局指定为关注/感兴趣的变体（VOC/VOI），这是基于许多因素的，包括它们对疾病疫苗介导保护的潜在影响。为了确定和评估 VOC 和 VOI 的风险，我们分析了 14 种变体（614G、Alpha、Beta、Gamma、Delta、Epsilon、Zeta、Eta、Theta、Iota、Kappa、Lambda、Mu 和 Omicron）逃避 mRNA 疫苗诱导的抗体的能力。这些变体在中和和复制方面表现出不同程度的降低。尽管奥密克戎变体（BA.1、BA.1.1 和 BA.2）显示出最逃避中和的能力，但接种第三剂疫苗（加强针）后采集的血清仍然对该变体具有中等的中和活性。因此，在 COVID-19 大流行期间，接种疫苗仍然是一种有效的策略。
